Hypertension, Resistant to Conventional Therapy, Obstructive Sleep Apnea
Conditions
Brief summary
Resistant hypertension is defined as uncontrolled blood pressure (BP ≥ 140/90mmHg) despite the current use of three or more antihypertensive drugs at full doses, including a diuretic. Obstructive Sleep Apnea (OSA) is at high risk for cardiovascular morbidity and is highly prevalent in patients with resistant hypertension. The prospective observational POP-ART study will assess the efficacy of continuous positive airway pressure (CPAP) treatment on BP in patients with resistant hypertension and collect data from usual care.
Detailed description
Obstructive Sleep Apnea is highly prevalent in patients with resistant hypertension and several studies have assessed the effect of CPAP treatment on BP. But only few studies have raised data about the effect of CPAP treatment on BP in patients with resistant hypertension. Hypertension is moreover associated with increased arterial stiffness, but no data are available in patients with resistant hypertension. The purpose of this study is to demonstrate that OSA has a major impact in resistant hypertension, whose effects on BP and arterial stiffness can partially be reversible with CPAP treatment.
Interventions
None listed
Sponsors
University Hospital, Grenoble
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patient with resistant hypertension uncontrolled by 3 or more antihypertensive agents * Patient with severe OSA (apnea-hypopnea index \> 30 or \> or equal to 15 with excessive daytime sleepiness), or with mild to moderate OSA without excessive daytime sleepiness, or without OSA. * Ambulatory patient
Exclusion criteria
* Body mass index ≥40 kg/m2 * Other identifiable causes of hypertension * Contraindication to CPAP treatment or patient already treated with CPAP
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean variation in BP at 6 months, assessed by 24h ambulatory BP monitoring | 6 months from baseline assessment |
Secondary
| Measure | Time frame |
|---|---|
| OSA prevalence in patients with resistant hypertension | 6 months |
| BP variability assessed by home self BP measurments | 6 months |
| Arterial stiffness assessed by pulse wave velocity and QKD interval | 6 months |
| Antihypertensive treatment consumption | 6 months |
| CPAP treatment observance | 6 months |
Countries
France
Contacts
Primary ContactGilles Barone-Rochette, MD, PhD
Backup ContactJean-Louis Pepin, MD, PhD
Outcome results
None listed